SG11201909265QA - Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to - Google Patents

Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

Info

Publication number
SG11201909265QA
SG11201909265QA SG11201909265QA SG11201909265QA SG 11201909265Q A SG11201909265Q A SG 11201909265QA SG 11201909265Q A SG11201909265Q A SG 11201909265QA SG 11201909265Q A SG11201909265Q A SG 11201909265QA
Authority
SG
Singapore
Prior art keywords
international
piasmodium
seq
fragment
protein according
Prior art date
Application number
Inventor
Antonio Lanzavecchia
Joshua Hoong Yu Tan
Claudia Daubenberger
Brandon Sack
Original Assignee
Inst Res Biomedicine
Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute
Schweizerisches Tropen Und Public Health Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine, Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute, Schweizerisches Tropen Und Public Health Inst filed Critical Inst Res Biomedicine
Publication of SG11201909265QA publication Critical patent/SG11201909265QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date omit VIII °nolo VIII 11110 101111101111111 (10) International Publication Number WO 2018/193063 A2 25 October 2018 (25.10.2018) WIP0 I PCT (51) International Patent Classification: C07K 16/20 (2006.01) A61K 39/015 (2006.01) Published: A61K 38/03 (2006.01) A61P 33/06 (2006.01) — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (21) International Application Number: — with sequence listing part of description (Rule 5.2(a)) PCT/EP2018/060113 (22) International Filing Date: 19 April 2018 (19.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/487,266 19 April 2017 (19.04.2017) US (71) Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE [CH/CH]; Via Vincenzo Vela 6, 6500 Bellinzona (CH). (72) Inventors: LANZAVECCHIA, Antonio; Via ai Ronchi 6, 6948 Porza (CH). TAN, Joshua Hoong Yu; 4, Jalan Sungai Beranang 32/56, Bukit Rimau, Shah Alam, 40460 (MY). DAUBENBERGER, Claudia; Am Lerchenbuck 17, 79379 Millheim (DE). SACK, Brandon; 1156 Alki Ave SW, Apt 103, Seattle, Washington 98109 (US). (74) Agent: VON STOSCH, Andreas et al.; Prinzregentenstr. 22, 80538 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). O (54) Title: NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO PLASMODIUM SPOROZOITES (57) : The present invention provides a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1, for 00 example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of piasmodium circum- sporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1. The O antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and/or C prevention of malaria.
SG11201909265Q 2017-04-19 2018-04-19 Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to SG11201909265QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487266P 2017-04-19 2017-04-19
PCT/EP2018/060113 WO2018193063A2 (en) 2017-04-19 2018-04-19 Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Publications (1)

Publication Number Publication Date
SG11201909265QA true SG11201909265QA (en) 2019-11-28

Family

ID=62063036

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909265Q SG11201909265QA (en) 2017-04-19 2018-04-19 Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

Country Status (11)

Country Link
US (1) US20200093909A1 (en)
EP (1) EP3612562A2 (en)
JP (2) JP7278259B2 (en)
KR (1) KR102595238B1 (en)
CN (2) CN110945022B (en)
AU (1) AU2018253918A1 (en)
BR (1) BR112019021824A2 (en)
CA (1) CA3058979A1 (en)
EA (1) EA201992434A1 (en)
SG (1) SG11201909265QA (en)
WO (1) WO2018193063A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019051642A1 (en) * 2017-09-12 2019-03-21 广州中科蓝华生物科技有限公司 Kit for transfecting intracellular parasites and use thereof
JP2021519599A (en) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ Antigenic OSPA polypeptide
JP2021519598A (en) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ Antigenic Epstein-Barr virus polypeptide
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
EP3962523A2 (en) * 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2021001351A1 (en) * 2019-07-01 2021-01-07 Deutsches Krebsforschungszentrum Plasmodium antibodies
US20220280632A1 (en) * 2019-07-24 2022-09-08 Bryce Chackerian Malaria immunogen and methods for using same
EP4041776A1 (en) * 2019-10-09 2022-08-17 The Hospital for Sick Children Immunogenic peptides, compositions, and methods for the treatment and/or prevention of malaria
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
KR20230080396A (en) * 2020-08-06 2023-06-07 더 맥파레인 버넷 인스티튜트 포 메디칼 리서치 앤드 퍼블릭 헬스 리미티드 immunogenic composition

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US20030119733A1 (en) * 1992-09-17 2003-06-26 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6207242B1 (en) 1995-12-28 2001-03-27 Hoffman Environmental System, Inc. Laminated package with enhanced interior and exterior
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
SK18602000A3 (en) 1998-06-08 2001-07-10 Sca Emballage France Fast flattening packaging
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
EP1386923B1 (en) 2001-04-17 2008-08-13 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine derivatives
DK1719511T3 (en) 2001-11-16 2009-04-14 Coley Pharm Group Inc N- [4- (4-amino-2-ethyl-1H-imidazo [4,5-c] quinolin-1-yl) butyl] methanesulfonamide, a pharmaceutical composition comprising the same, and use thereof
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN101190946A (en) * 2006-12-01 2008-06-04 中国人民解放军第二军医大学 Recombination plasmodium falciparum circumsporozoite surface protein and its preparation method and use
CN101802197A (en) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 Single-chain FC (ScFc) regions, binding polypeptides comprising same, and methods related thereto
ES2525346T3 (en) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
AU2011313913A1 (en) * 2010-10-10 2013-05-02 Aduro Biotech Methods and compositions for inducing a T-cell response to Plasmodium species
US20150359869A1 (en) * 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition

Also Published As

Publication number Publication date
US20200093909A1 (en) 2020-03-26
CA3058979A1 (en) 2018-10-25
WO2018193063A2 (en) 2018-10-25
KR102595238B1 (en) 2023-10-26
CN110945022B (en) 2024-04-05
JP2020520674A (en) 2020-07-16
AU2018253918A1 (en) 2019-10-31
JP2023058633A (en) 2023-04-25
CN118085055A (en) 2024-05-28
JP7278259B2 (en) 2023-05-19
EA201992434A1 (en) 2020-03-30
EP3612562A2 (en) 2020-02-26
WO2018193063A3 (en) 2019-01-03
BR112019021824A2 (en) 2020-06-02
CN110945022A (en) 2020-03-31
KR20200141917A (en) 2020-12-21

Similar Documents

Publication Publication Date Title
SG11201909265QA (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201808709VA (en) T cell receptors
SG11201808750PA (en) T cell receptors
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201900482SA (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201806340YA (en) Zika virus vaccine
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201807912SA (en) Vaccine against rsv
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201808751SA (en) T cell receptors
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201909353VA (en) Hbv vaccine
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201408054RA (en) Pegylated oxm variants
SG11201901790YA (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof